Patent ID: 8920811

Claim:
A recombinant adenovirus for treating malignancy of over-expressing proto-oncogene Neu/erb B2, comprising an expression cassette consisting of a promoter, a fused gene, an internal ribosome entry site (IRES) fragment, a Mda-7/IL-24 gene and a SV40 poly adenine fragment, wherein said expression cassette is inserted in E1 deletion region of said recombinant adenovirus, and wherein said expression cassette comprises the characteristics of that as following: (a) A DNA fragment coding a signal peptide of interleukin-2 (IL-2) formed by 20 amino acids is fused into the 5′-terminal of said fused gene; (b) Said fused gene is composed of the nucleotide sequences encoding the light chain variable region peptide and the heavy chain variable region peptide of humanized monoclonal antibody against proto-oncogene neu/erb B2; (c) The encoded peptide of the light chain variable region is fused to the encoded peptide of the heavy chain variable region by a linker composed of amino acid: -Gly-Gly-Gly-Gly-Gly-Ser-; (d) Within said expression cassette, N-terminal of said fused gene is ligated to downstream of CMV promoter via endonuclease Nhe1 site and its C-terminal is ligated to upstream of the IRES fragment via endonuclease Not1 site; (e) Within said expression cassette, N-terminal of Mda-7/IL-24 is ligated to downstream of IRES fragment via endonuclease Sma1 site and its C-terminal is ligated to upstream of SV40 poly adenine via endonuclease Xba1 site.